Evidence map›Paper›PMID 38131790›Full record

ArticleBiosensors2023

Antibody Profiling: Kinetics with Native Biomarkers for Diagnostic Assay and Drug Developments.

Ute Jucknischke, Sebastian Friebe, Markus Rehle, Laura Quast, Sven H Schmidt

Open access · goldAbstract read
In one paragraph

Article in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ute JucknischkeDiagnostic Solutions, Reagent Research and Design, Department Antibody and Protein Technologies, (DSRRA) at Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
Sebastian FriebeDiagnostic Solutions, Reagent Research and Design, Department Antibody and Protein Technologies, (DSRRA) at Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
Markus RehleDiagnostic Solutions, Reagent Research and Design, Department Antibody and Protein Technologies, (DSRRA) at Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
Laura QuastDiagnostic Solutions, Reagent Research and Design, Department Antibody and Protein Technologies, (DSRRA) at Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
Sven H SchmidtDiagnostic Solutions, Reagent Research and Design, Department Antibody and Protein Technologies, (DSRRA) at Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite remarkable progress in applied Surface Plasmon Resonance (SPR)-based methods, concise monitoring of kinetic properties for native biomarkers from patient samples is still lacking. Not only are low concentrations of native targets in patient samples, often in the pM range, a limiting and challenging factor, but body fluids as complex matrices furthermore complicate measurements. The here-described method enables the determination of kinetic constants and resulting affinities for native antigens from patients' cerebrospinal fluid (CSF) and sera binding to antibodies. Using a significantly extended target-enrichment step, we modified a common sandwich-assay protocol, based on a primary and secondary antibody. We successfully analyze antibody kinetics of native targets from a variety of origins, with consistent results, independent of their source. Moreover, native neurofilament light chain (NFL) was investigated as an exemplary biomarker. Obtained data reveal antibodies recognizing recombinant NFL with high affinities, while showing no, or only significantly weakened binding to native NFL. The indicated differences for recombinant vs. native material demonstrate another beneficial application. Our assay is highly suitable for gaining valuable insights into characteristics of native biomarkers, thus impacting on the binder development of diagnostic reagents or pharmaceutical drugs.

Indexed as

AntigensSurface Plasmon ResonanceAntibodiesBiomarkersHumansAntibodiesAntigensBiomarkersBiacoreGDF15interaction kineticsnative biomarkerneurofilament light chainNFLSPRsurface plasmon resonance

Identifiers

PMID38131790
PMCPMC10742008
OpenAlexW4389818040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.